Behavioral Responses of Patients in AIDS Treatment Programs: Sexual Behavior in Kenya
-
Harsha Thirumurthy
Abstract
We estimate changes in sexual behavior for HIV-positive individuals enrolled in an AIDS treatment program using longitudinal household survey data collected in western Kenya. We find that sexual activity is lowest at the time that treatment is initiated and increases significantly in the subsequent six months, consistent with the health improvements that result from ART treatment. More importantly, we find large and significant increases of 10 to 30 percentage points in the reported use of condoms during last sexual intercourse. The increases in condom use appear to be driven primarily by a program effect, applying to all HIV clinic patients regardless of treatment status.
©2012 Walter de Gruyter GmbH & Co. KG, Berlin/Boston
Articles in the same Issue
- Article
- Behavioral Responses of Patients in AIDS Treatment Programs: Sexual Behavior in Kenya
- Optimal Alcohol Taxes for Australia
- A Prescription for Drug Formulary Evaluation: An Application of Price Indexes
- Nutrient Demand in Food Away from Home
- The Option Value of Innovation
- The Distributional Effects of Health Reform Limits on Flexible Spending Accounts
- The Value of Patent Expiration
- Formal and Informal Care: An Empirical Bayesian Analysis Using the Two-part Model
- Can Centralization of Cancer Surgery Improve Social Welfare?
- A Reexamination of the Costs of Medical R&D Regulation
Articles in the same Issue
- Article
- Behavioral Responses of Patients in AIDS Treatment Programs: Sexual Behavior in Kenya
- Optimal Alcohol Taxes for Australia
- A Prescription for Drug Formulary Evaluation: An Application of Price Indexes
- Nutrient Demand in Food Away from Home
- The Option Value of Innovation
- The Distributional Effects of Health Reform Limits on Flexible Spending Accounts
- The Value of Patent Expiration
- Formal and Informal Care: An Empirical Bayesian Analysis Using the Two-part Model
- Can Centralization of Cancer Surgery Improve Social Welfare?
- A Reexamination of the Costs of Medical R&D Regulation